Literature DB >> 26802717

Re: Berg et al.: Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol (Ophthalmology 2015;122:146-52).

Robert L Avery1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26802717     DOI： 10.1016/j.ophtha.2015.08.031

Source DB:  PubMed          Journal:  Ophthalmology        ISSN： 0161-6420            Impact factor:   12.079


× No keyword cloud information.
  4 in total

1.  Serious Adverse Events with Bevacizumab or Ranibizumab for Age-related Macular Degeneration: Meta-analysis of Individual Patient Data.

Authors: 
Journal:  Ophthalmol Retina       Date:  2017-04-12

Review 2.  A Systematic Review of the Treat and Extend Treatment Regimen with Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration.

Authors:  Maria Gemenetzi; Praveen J Patel
Journal:  Ophthalmol Ther       Date:  2017-04-27

3.  SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.

Authors:  Robert L Avery; Alessandro A Castellarin; Nathan C Steinle; Dilsher S Dhoot; Dante J Pieramici; Robert See; Stephen Couvillion; Maʼan A Nasir; Melvin D Rabena; Mauricio Maia; Sherri Van Everen; Kha Le; William D Hanley
Journal:  Retina       Date:  2017-10       Impact factor: 4.256

4.  Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.

Authors:  Emily Li; Simone Donati; Kristina B Lindsley; Magdalena G Krzystolik; Gianni Virgili
Journal:  Cochrane Database Syst Rev       Date:  2020-05-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.